

13 May 2025

Belluscura plc
("Belluscura" or the "Company")

Response to Share Price Movement

Belluscura plc (AIM: BELL), a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies, notes the recent movements in its share price.

On Friday 9 May 2025 the Company issued a notification which included, *inter alia*, a comprehensive trading update and commencement of strategic review. There have been no notifiable developments since the publication of that announcement. As stated in that notification, the Company will provide further updates as and when appropriate.

Enquiries:

For further information please contact:

Belluscura plc
Paul Tuson, Chairman
Robert Rauker, Chief Executive Officer

Tel: +44 (0)20 3128 8100

SPARK Advisory Partners Limited
Nominated Adviser
Neil Baldwin / Jade Bayat

Tel: +44 (0)20 3368 3550

Dowgate Capital Limited
Joint Broker
James Serjeant / Colin Climie (Sales and Corporate Broking)
Russell Cook / Daniel Ingram (Corporate Finance)

Tel: +44 (0)20 3903 7715

Allenby Capital Ltd
Joint Broker
Guy McDougall / Amrit Nahal (Sales and Corporate Broking)
Jeremy Porter / Lauren Wright (Corporate Finance)

Tel: +44 (0)20 3328 5656

MHP
Financial PR & Investor Relations
Katie Hunt/Matthew Taylor

Tel: +44 (0)20 3128 8100
email: belluscura@mhpgroup.com

For further information, please visit <https://ir.belluscura.com/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

SPCBBGDUDUBDGUX